A5008142909- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Breast Implant and Reconstruction
- Breast Lesions and Carcinomas
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
- Glioma Diagnosis and Treatment
- Reconstructive Surgery and Microvascular Techniques
- Cancer survivorship and care
- Medical Imaging Techniques and Applications
- Bone health and treatments
- Chronic Lymphocytic Leukemia Research
- Skin Diseases and Diabetes
- Autoimmune Bullous Skin Diseases
- Genital Health and Disease
- Hematological disorders and diagnostics
- Radiopharmaceutical Chemistry and Applications
- Mesenchymal stem cell research
- Thyroid and Parathyroid Surgery
- Brain Metastases and Treatment
- Cancer, Stress, Anesthesia, and Immune Response
- Dermatological diseases and infestations
- Cancer Diagnosis and Treatment
German Breast group
2023-2025
University of Rostock
2024
University Hospital Heidelberg
2024
University Medical Center Hamburg-Eppendorf
2014-2024
University Hospital Ulm
2024
University Hospital and Clinics
2024
Agaplesion Markus Hospital
2024
Universität Hamburg
2014-2024
Breast Center
2024
Heidelberg University
2024
Hematogenous spread of glioblastoma multiforme (GBM) might be responsible for reported extracranial metastases and transmission GBM by organ transplantation.
Objective: This study aimed to investigate the feasibility and accuracy of non-radioactive TLN biopsy TAD in routine clinical practice. Background Data: involves (TLNB) sentinel lymph node was recently introduced as a new standard for less invasive axillary staging BC patients undergoing neoadjuvant systemic therapy (NST); however, evidence is limited. Methods: The SenTa prospective registry conducted at 50 centers. Patients with who nderwent clip insertion into most suspicious were...
Highlights•Classical intrinsic subtypes change during neoadjuvant therapy from LumB to LumA•A reverse-transition back is observed in metastatic disease•Improved dimension reduction by comparison of pre- and post-therapeutic samples•Identification adaptive prognostic subsets high-risk luminal breast cancerSummaryWe evaluate therapy-induced molecular heterogeneity longitudinal samples high-risk, hormone-receptor positive/HER2-negative cancer patients with residual tumor after chemotherapy the...
BackgroundWhether surgical axillary staging as part of breast-conserving therapy can be omitted without compromising survival has remained unclear.MethodsIn this prospective, randomized, noninferiority trial, we investigated the omission surgery compared with sentinel-lymph-node biopsy in patients clinically node-negative invasive breast cancer staged T1 or T2 (tumor size, ≤5 cm) who were scheduled to undergo surgery. We report here per-protocol analysis disease–free (the primary efficacy...
Abstract Backgound: The GeparOLA study evaluated paclitaxel(P) plus olaparib(O) in neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer (eBC) homologous recombination deficiency (HRD). HRD was defined by high HRD-score or germline(g)/tumor(t) BRCA1/2 mutations (g/tBRCA1/2mut). Here, we report long-term outcome data. Patients and Methods: (NCT02789332) a randomized, multicenter, prospective, open-label, phase II trial. eBC, HRD, indication (cT2-cT4a-d cT1c cN+...
Combination of chemotherapy with (dual) ERBB2 blockade is considered standard in hormone receptor (HR)-positive/ERBB2-positive early breast cancer (EBC). Despite some promising data on endocrine therapy (ET) combination dual HR-positive/ERBB2-positive BC, to our knowledge, no prospective comparison neoadjuvant vs ET plus particular focus molecular markers has yet been performed.
The nodal burden of patients with residual isolated tumor cells (ITCs) in the sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy (NAC) (ypN0i+) is unknown, and axillary management not standardized. We investigated rates additional positive (LNs) at node dissection (ALND) oncologic outcomes ypN0i+ treated without ALND.
PURPOSE To assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free (iDFS) in randomized clinical trials (RCTs) early breast cancer (BC). METHODS Individual patient data neoadjuvant RCTs with available on pCR, iDFS, OS were included analysis. We used coefficient determination R 2 from weighted linear regression models to quantify association between treatment effects surrogate end points. RESULTS Eleven RCTs, a total 15...
The PI3K signaling pathway is frequently dysregulated in breast cancer, and mutations PIK3CA are relevant for therapy resistance HER2-positive (HER2pos) cancer. Mutations exons 9 or 20 may have different impacts on response to neoadjuvant chemotherapy-based treatment regimens.
Background/Aim: The purpose of this study was to evaluate, whether radio frequency identification (RFID) labeling axillary lymph nodes (LNs) for the use targeted resection is feasible in primary breast cancer patients with suspicious LNs. Patients and Methods: We analyzed 10 consecutive where RFID technique used intraoperative detection LNs without preceding neoadjuvant chemotherapy (NACT). compared specifics these procedures sentinel node biopsies (SLNB) cN0 situation. Results:...
BackgroundNeoadjuvant chemotherapy (NACT) is routinely used for patients with triple-negative breast cancer (TNBC). Upfront breast-conserving therapy (BCT) consisting of surgery (BCS) and adjuvant radiotherapy (RT) has been shown to be associated improved outcome in early TNBC as compared mastectomy.MethodsWe identified 2632 from the German Breast Group meta-database. Patients cT1-2 cN0 ypN0, available follow-up data were enrolled. Data 1074 8 prospective NACT trials available. Endpoints...
PURPOSE The aim of the current work was to clarify whether a preoperative lymphoscintigraphy (LSG) enhances staging accuracy sentinel lymph node biopsy (SLNB). PATIENTS AND METHODS In prospective, multicenter, randomized phase III trial, patients with cN0 early breast cancer or extensive/high-grade ductal carcinoma in situ planned for standard radioactive-labeled colloid LSG subsequent SLNB were randomly assigned 1:1 receive either knowledge findings without. As false-negative rate...
<b>Aim:</b> The risk of recurrence in breast cancer depends on factors such as treatment but also the intrinsic subtype. We analyzed for local, loco-regional and systemic recurrence, evaluated differences different molecular subtypes. <b>Material Methods:</b> A total 3054 patients who underwent surgery followed by adjuvant at HSK hospital or Essen Mitte Hospital between 1998 2011 were analyzed. Based immunohistochemical parameters, cancers divided into following subgroups: luminal A, B...
<b><i>Background:</i></b> This study presents first feasibility experiences with a new 3-dimensional (3D) marker clip system in clinical practice. The rate of complete responses the treatment breast cancer patients is increasing; additionally, change to targeted axillary dissection being considered after neoadjuvant chemotherapy (NACT). Consequently, clips are needed which reliable and easy handle even lymph node system. <b><i>Methods:</i></b>...
515 Background: HR+/HER2+ breast cancer (BC) is a distinct entity associated with better prognosis compared to HR-/HER2+ BC. However, combination of chemotherapy (CT) (dual) anti-HER2 blockade standard in HER2+ early BC (EBC), irrespective HR-status. Despite some promising data on endocrine therapy (ET) dual EBC and metastatic BC, no prospective comparison neoadjuvant CT vs. ET + HER2-blockade has yet been performed. Methods: In the WSG TP-II phase II-trial (NCT03272477; Sponsor: Palleos...